Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Wearable HRV Biofeedback for Stress in Dementia Caregivers (CARE-COHERENCE)

Low-cost Wearable Heart Rate Variability Biofeedback as a Nurse-led Intervention to Reduce Stress in Informal Caregivers of People With Dementia: a Prospective Controlled Non-randomized Interventional Trial

This study will evaluate whether a nurse-led heart rate variability (HRV) biofeedback programme supported by a low-cost wearable sensor reduces autonomic dysregulation and perceived stress in informal caregivers of people with dementia. Participants will be prospectively allocated, without randomization, at the day-care-centre level. Before enrolment, the six centres will be characterised according to centre size, estimated number of eligible caregivers and expected recruitment volume, and arranged into three approximately matched pairs. One centre in each pair will implement CARE-COHERENCE and the other will serve as a concurrent comparison centre under a pre-specified operational implementation plan. Follow-up will continue for 12 months.

Studieöversikt

Detaljerad beskrivning

Approximately 100 informal caregivers of older people with dementia attending one of six participating day-care centres will be enrolled. The intervention group will receive an 8-week HRV-biofeedback programme in addition to usual caregiver support. The comparison group will receive usual caregiver support during the 12-month study period and will be offered access to programme materials after completion of the final assessment. The primary outcome is change in resting root mean square of successive differences (RMSSD) from baseline to 6 months. Perceived stress is the key secondary outcome. Assessments occur at baseline, 8 weeks, 6 months and 12 months.

Studietyp

Interventionell

Inskrivning (Beräknad)

100

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Cantabria
      • Santander, Cantabria, Spanien
        • Rekrytering
        • Hospital Universitario Marqués de Valdecilla
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Adult (18 years or older) self-identified informal, unpaid caregiver of an older person with a clinical diagnosis of dementia attending one of the participating day-care centers.
  • Providing an average of at least 28 hours of unpaid care per week for a minimum of 3 months.
  • Able to understand study procedures and provide written informed consent.
  • Able to use a smartphone and a simple wearable device, independently or with brief study support.

Exclusion Criteria:

  • Persistent or clinically significant cardiac arrhythmia preventing reliable interbeat-interval analysis.
  • Pacemaker-dependent rhythm or another condition that, in the investigator's judgment, precludes valid heart rate variability assessment.
  • Current participation in formal heart rate variability biofeedback or structured resonance-frequency breathing training, or equivalent training within the previous 3 months.
  • Severe uncontrolled psychiatric illness or cognitive impairment precluding informed consent or meaningful participation.
  • Concurrent enrollment in another structured stress-reduction intervention trial.
  • Note: use of heart rate-modifying medication, including beta-blockers, is not an exclusion criterion. Medication use is documented prospectively and considered in prespecified sensitivity analyses.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Stödjande vård
  • Tilldelning: Icke-randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Enda

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: CARE-COHERENCE HRV biofeedback program

Participants receive an 8-week nurse-led heart rate variability (HRV) biofeedback program in addition to usual caregiver support. At program entry, an individual resonance frequency is determined using paced-breathing trials across a prespecified range of approximately 4.5 to 6.5 breaths per minute. The active phase comprises four weekly nurse-led sessions of approximately 60 minutes during weeks 1-4, followed by structured supported home practice during weeks 5-8. Sessions cover the physiological rationale for HRV biofeedback, paced breathing at the selected training frequency, interpretation of simple wearable feedback, management of common practice difficulties, and a brief positive-emotion self-regulation strategy. Participants are encouraged to practice approximately 10 minutes twice daily, or to reach a minimum accumulated practice target of 70 minutes per week. One booster contact occurs at month 3.

Nurse-delivered behavioral self-regulation training combining individualized resonance-frequency paced breathing with real-time HRV feedback from a low-cost wrist- or chest-worn sensor capable of recording interbeat intervals, paired with a compatible training application. Dose: four supervised sessions of approximately 60 minutes in weeks 1-4, delivered individually or in small groups, followed by supported home practice in weeks 5-8 (target 10 minutes twice daily, or at least 70 accumulated minutes per week), plus one booster contact at month 3. Training frequency is set per participant during an initial paced-breathing assessment across approximately 4.5-6.5 breaths per minute. A brief positive-emotion self-regulation strategy is included. The device model, firmware, and application version are prespecified before recruitment and held constant where possible. Adherence is derived from device and application logs and a participant practice log.

Andra namn:
  • Resonansfrekvens andningsträning
  • CARE-COHERENCE program
Inget ingripande: Usual caregiver support

Participants continue to receive usual caregiver support, including routine clinical care, information, and standard services available through the participating day-care centers and other routine health and social care services. They do not receive structured resonance-frequency breathing training or HRV biofeedback from the study team at any point during the 12-month study period. After the 12-month assessment, participants in this group will be offered access to the CARE-COHERENCE educational materials and a program orientation session.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in resting RMSSD
Tidsram: Baseline and 6 months

Root mean square of successive differences (RMSSD) derived from a standardised resting interbeat-interval recording obtained with the study wearable sensor and processed according to a prespecified HRV analysis protocol. Higher values indicate greater vagally mediated heart rate variability.

Baseline and 6 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in perceived stress (Perceived Stress Scale, PSS-10)
Tidsram: Baseline, 8 weeks, 6 months and 12 months

Perceived stress measured with the 10-item Perceived Stress Scale (PSS-10). Total score ranges from 0 to 40. Higher scores indicate greater perceived stress; a decrease indicates improvement. Analyzed as change from baseline and as the follow-up value adjusted for the baseline score. This is the key secondary outcome.

Baseline, 8 weeks, 6 months and 12 months
Maintenance of resting RMSSD at 12 months
Tidsram: Baseline and 12 months

Root mean square of successive differences (RMSSD, in milliseconds) derived from a standardized resting interbeat-interval recording obtained with the study wearable sensor and processed with the prespecified HRV analysis pipeline. Higher values indicate greater vagally mediated heart rate variability. Assesses whether any intervention effect on the primary outcome is maintained six months after the primary endpoint.

Baseline and 12 months
Change in caregiver burden (Zarit Burden Interview, ZBI-22)
Tidsram: Baseline, 8 weeks, 6 months and 12 months

Caregiver burden measured with the 22-item Zarit Burden Interview. Total score ranges from 0 to 88. Higher scores indicate greater burden; a decrease indicates improvement.

Baseline, 8 weeks, 6 months and 12 months
Change in resting SDNN
Tidsram: Baseline, 8 weeks, 6 months and 12 months

Standard deviation of normal-to-normal interbeat intervals (SDNN, in milliseconds) from the same standardized resting recording used for the primary outcome. Higher values indicate greater overall heart rate variability.

Baseline, 8 weeks, 6 months and 12 months
Change in mean resting heart rate
Tidsram: Baseline, 8 weeks, 6 months and 12 months

Mean heart rate in beats per minute derived from the standardized resting interbeat-interval recording.

Baseline, 8 weeks, 6 months and 12 months
Change in well-being (WHO-5 Well-Being Index)
Tidsram: Baseline, 8 weeks, 6 months and 12 months

Well-being measured with the five-item WHO-5 Well-Being Index. The raw score ranges from 0 to 25 and is multiplied by 4 to give a percentage score from 0 to 100. Higher scores indicate better well-being; an increase indicates improvement.

Baseline, 8 weeks, 6 months and 12 months
Change in anxiety and depressive symptoms (Hospital Anxiety and Depression Scale, HADS)
Tidsram: Baseline, 8 weeks, 6 months and 12 months

Symptoms measured with the Hospital Anxiety and Depression Scale. The HADS-Anxiety and HADS-Depression subscales are reported separately; each ranges from 0 to 21. Higher scores indicate more severe symptoms; a decrease indicates improvement.

Baseline, 8 weeks, 6 months and 12 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Samarbetspartners

Utredare

  • Huvudutredare: Carmen Sarabia Cobo, University of Cantabria

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

1 oktober 2026

Primärt slutförande (Beräknad)

30 april 2028

Avslutad studie (Beräknad)

31 oktober 2028

Studieregistreringsdatum

Först inskickad

5 november 2026

Först inskickad som uppfyllde QC-kriterierna

5 november 2026

Första postat (Faktisk)

12 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

12 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

5 november 2026

Senast verifierad

1 augusti 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

De-identified individual participant data underlying the results reported in the primary publication, together with the data dictionary, may be made available to qualified researchers whose proposed use has been approved by the study team. Data will be shared subject to a data-sharing agreement, applicable ethics committee requirements, and EU General Data Protection Regulation and Spanish data-protection law. Requests should be addressed to the corresponding author.

Tidsram för IPD-delning

Beginning 6 months after publication of the primary results report, with no specified end date.

Kriterier för IPD Sharing Access

Requests from qualified researchers with a methodologically sound proposal, reviewed by the study team, and subject to a signed data-sharing agreement and to applicable ethics and EU/Spanish data-protection requirements. Requests should be sent to the corresponding author.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera